Cubist Systematic Strategies, LLC Next Cure, Inc. Transaction History

Cubist Systematic Strategies, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$2.72 - $5.19 $33,083 - $63,125	12,163 New	12,163 $33,000
Q1 2022 May 16, 2022	SELL	$4.76 - $6.24 $87,503 - $114,709	-18,383 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$5.7 - $9.1 $22,805 - $36,409	4,001 Added 27.82%	18,383 $110,000
Q3 2021 Nov 15, 2021	SELL	$6.74 - $8.02 $68,889 - $81,972	-10,221 Reduced 41.54%	14,382 $97,000
Q2 2021 Aug 16, 2021	BUY	$7.6 - $10.28 $57,106 - $77,243	7,514 Added 43.97%	24,603 $198,000
Q1 2021 May 17, 2021	SELL	$9.81 - $13.88 $65,707 - $92,968	-6,698 Reduced 28.16%	17,089 $171,000
Q4 2020 Feb 16, 2021	SELL	$9.47 - $12.43 $260,159 - $341,476	-27,472 Reduced 53.59%	23,787 $259,000
Q3 2020 Nov 16, 2020	BUY	$8.15 - $21.17 $267,075 - $693,740	32,770 Added 177.24%	51,259 $451,000
Q2 2020 Aug 14, 2020	BUY	$21.19 - $40.2 $391,781 - $743,257	18,489 New	18,489 $396,000

15.9M

Ticker NXTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,748,800
Market Cap $20.8M
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.